13,789 Shares in GeneDx Holdings Corp. $WGS Acquired by Clough Capital Partners L P

Clough Capital Partners L P acquired a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,789 shares of the company’s stock, valued at approximately $1,793,000.

Several other institutional investors also recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its position in shares of GeneDx by 4.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after purchasing an additional 52,322 shares during the last quarter. Vanguard Group Inc. grew its position in GeneDx by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock valued at $154,650,000 after acquiring an additional 18,647 shares during the last quarter. Franklin Resources Inc. grew its position in GeneDx by 60.4% during the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after acquiring an additional 411,607 shares during the last quarter. Westfield Capital Management Co. LP grew its position in GeneDx by 87.1% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock valued at $132,435,000 after acquiring an additional 474,167 shares during the last quarter. Finally, ARK Investment Management LLC grew its position in GeneDx by 35.3% during the fourth quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock valued at $78,629,000 after acquiring an additional 157,582 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.

GeneDx Stock Performance

NASDAQ:WGS opened at $56.42 on Thursday. The stock has a market cap of $1.68 billion, a P/E ratio of -21.05 and a beta of 1.96. The firm’s fifty day simple moving average is $54.54 and its 200 day simple moving average is $87.44. GeneDx Holdings Corp. has a twelve month low of $32.21 and a twelve month high of $170.87. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter last year, the firm earned ($0.23) EPS. As a group, research analysts predict that GeneDx Holdings Corp. will post -1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on WGS. Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. BTIG Research decreased their target price on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Guggenheim dropped their price target on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Wall Street Zen cut shares of GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings cut shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Several law firms, including Rosen, Kahn Swick & Foti, Bernstein Liebhard, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Pomerantz, Gross Law Firm and Schall, issued reminders or notices about the ongoing securities class action against GeneDx and the August 3 lead-plaintiff deadline. Article: WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
• Neutral Sentiment: One filing specifically alleges the stock’s decline was linked to alleged acquisition-performance misrepresentations and a large write-off related to the Fabric Genomics acquisition, keeping investor focus on past execution risks. Article: GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition
• Negative Sentiment: The lawsuits and repeated investor alerts may add legal overhang and could increase volatility in GeneDx shares as shareholders assess possible damages and reputational risk. Article: Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act

Insider Buying and Selling at GeneDx

In other news, Director Keith A. Meister acquired 533,758 shares of the stock in a transaction on Thursday, May 7th. The stock was acquired at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the transaction, the director owned 3,761,908 shares of the company’s stock, valued at $142,425,836.88. This represents a 16.53% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Casdin Capital, Llc acquired 185,000 shares of the stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the transaction, the director directly owned 3,367,164 shares of the company’s stock, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 2,256,420 shares of company stock valued at $93,144,340 and have sold 54,402 shares valued at $3,395,647. Company insiders own 25.17% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.